1	2	3	4	5
11	Sustamon 250 Inj.	Each 1 ml. contains Testosterone Propionate 30 mg., Testosterone Isocarpoate 60 mg, Testosterone Phenylpropionate 60 mg, Testosterone Decanoate 100 mg. 1 amp.	22.54	35.90
12	Testanon 25 Inj.	Each 1 ml. contains Testosterone Propionate 25 mg. 3 amp. 20 amp.	1.66/amp	4.60/amp
13	Testanon 50 Inj.	Each 1 ml. contains Testosterone Phenylpropionate 50 mg.— 3 amp.	7.20/amp	11.00/amp

Sales turn over of formulation

859. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) what was the annual sales turn over of formulations of Alkali Chemical Corporation, Ciba-Geigy, E. Merck, Geoffary Manners, Glaxo, Merok Sharp and Dhome, Organon Wyeth Labs., Richardson Hindustan and Suhrid Geigy during the last three years, year-wise;

(b) what was the sales turnover of each company separately of Harmones, Cartico-steriods, Vitamin Preparations during the last three years, year-wise;

(c) what was the overall profitability of formulations of each company during the last three years, year-wise;

(d) whether any of these companies are producing any essential drugs|medicines falling under categories I and II of DPCO 1979; and

(e) if so, name of the Drugs|medicine and the company alongwith sales turnover of each during the last three years, year-wise and what was the percentage of total sales turnover during the same period?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETRO-CHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) A Statement giving the information to the extent available is attached at Annexure-I.

(b) Sales turnover of individual formulation and various therapeutic groups is not monitored.

(c) Information to the extent available about overall profits on the formulations activity of the companies referred to in Part (a) is given in the attached Statement at Annexure II.

(d) and (e) Among the companies referred to in reply to part (a), the following companies are producing

Category I and Category II formulations mentioned against each:

Sl. No.	Name of the company	Name of Category I & Cat. II formulations manufactured by the company
1	Merind Limited	(1) Merstrep (2) Trycin Capsules
2	Wyeth Laboratories Ltd.	(1) Wysolone Tablets (2) Prednisolone Tabs.
3	Geoffrey Manners & Co. Limited . .	(1) Vitamycetin Caps. (2) Vitamycetin Syrup
4	Glaxo Laboratories (India) Limited . .	(1) Triple Antigen (2) Tetanus Toxoid (3) Piperazine Tablets (4) *Piperazine Syrup* (5) Piperazine Liquid (6) Delta-Efcorlin
5	Richardson Hindustan Limited . .	Nil

Sales turnover of these formulations is not monitored. As such, the percentage of sales turnover of these formulations to the total sales turnover of formulations cannot be determined.

Annexure-I

Sl. No.	Name of the Company	Year Ending	Sales Turnover of Formulations (Rs. / lakhs)
1	M/s. Glaxo Laboratories (India) Limited .	June, 1982	8094·50
		June, 1983	9219·30
		June, 1984	9412·10
2	M/s. Merind Limited	December, 1982	1626·18
		December, 1983	1342·08
		December, 1984	1947·17
3	M/s. Wyeth Laboratories Limited .	October, 1982	766.87
		October, 1983	611.28
		October, 1984	947.87
4	M/s. Geoffrey Manners & Co. Limited .	October, 1982	Not available
		October, 1983	1366.53
		October, 1984	1446·97
5	M/s. Richardson Hindustan Limited . .	June, 1982	1924·00
		June, 1984	2847·00
		June, 1985	595·00

Annexure-II

Sl. No.	Name of the Company	Year ending	Profit before tax on formulation activity (Rs./lakhs)
1	M/s. Glaxo Labs. (India) Ltd.	June, 1982	579·6
		June, 1983	795·7
		June, 1984	682·20
2	M/s. Merind Ltd.	December, 1982	79·90
		December, 1983	3·69
		December, 1984	167·20
3	M/s. Wyeth Labs. Ltd.	October, 1982	69·76
		October, 1983	44·88
		October, 1984	46·60
4	M/s. Geoffery Manners & Co. Ltd.	October, 1982	N. A.
		October, 1983	159·72
		October, 1984	100·01
5	M/s. Richardson Hindustan Ltd.	June, 1982	198·00
		June, 1984	279·00
		June, 1985	48·00

Production of steriods

860. SHRI RAFIQUE ALAM: Will the Minister of INDUSTRY be pleased to state:

(a) the names of the units licenced to produce harmones, steriods and their intermediates from basic stages i.e. Diosgenin and Solasodine alongwith the names of specific drugs and intermediates licenced to each, capacity permitted and production of each during the last three years, year-wise.

(b) whether it is a fact that indigenous technology for producing steriods was developed about 25 years back by a CSIR laboratory;

(c) if so, the name of the laboratory;

(d) whether it is also a fact that huge capacities were created for the production of steriods and its intermediates and the same are lying idle;

(e) whether it is also a fact that the basic materials i.e. Diosgenin and Solasodine are banned for import but the intermediates being manufactured from these are allowed for import under OGL; and

(f) if so, what were the basis for such recommendations by his Department

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M/s. Glaxo and M/s. Wyeth are licensed to produce Betamethasone and Prednisolone respectively from basic stage. M/s. Cadila and M/s. T.N. Dadha are licensed to produce Dexamethasone and Betamethasone respectively from